Oruka Therapeutics, Inc. (ORKA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.73B
Last updated: Nov 17, 2026 at 4:33 PM ET
Oruka Therapeutics, Inc. (ORKA) Stock Chart
Oruka Therapeutics (ORKA) has a latest price of $96.32 on Nov 17, 2026, 16.6% below its 52-week high of $115.52. Its price rose 255.7% over the past 12 months. The month-end price fell 79.6% over the 10 years through Oct 2026, a compound annual decline of 14.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $615.35 in Dec 2016 and its lowest $10.15 in Feb 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ORKA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ORKA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 12.2%, and over 6 months it rose 67.5%. The month-end price rose 350.8% over the 3 years through Oct 2026, a compound annual rate of 65.2%.
| Period | Change |
|---|---|
| 1 month | +29.3% |
| 3 months | -12.2% |
| 6 months | +67.5% |
| 12 months | +255.7% |
| 12 months, with dividends | +255.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +350.8% | +65.2% |
| 5 years | +194.5% | +24.1% |
| 10 years | -79.6% | -14.7% |
Price by Year
Its best calendar year was 2025, when the price rose 56.3%, and its weakest was 2018, when it fell 75.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $96.87 | +219.6% |
| 2025 | $30.31 | +56.3% |
| 2024 | $19.39 | -5.0% |
| 2023 | $20.41 | -28.3% |
| 2022 | $28.45 | +10.2% |
| 2021 | $25.81 | -46.4% |
| 2020 | $48.14 | -29.8% |
| 2019 | $68.55 | -4.8% |
| 2018 | $72.01 | -75.3% |
| 2017 | $291.48 | -52.6% |
Trading Range
The price is 7.2% above its 50-day average of $89.85 and 31.4% above its 200-day average of $73.29.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $96.32 | |
| 52-week high | $115.52 | -16.6% |
| 52-week low | $25.23 | +281.8% |
| 50-day average | $89.85 | +7.2% |
| 200-day average | $73.29 | +31.4% |
Price Risk
Over 3 years, its largest fall from a peak was 77.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.48 |
| Largest fall, 1 year | -36.4% |
| Largest fall, 3 years | -77.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ORKA
What is ORKA's 1-year price change?
Oruka Therapeutics's price rose 255.7% over the past 12 months. With dividends included, the 12-month total return was 255.7%.
What is ORKA's 5-year price change?
Oruka Therapeutics's month-end price rose 194.5% over the 5 years through Oct 2026, a compound annual rate of 24.1%. These figures leave out dividends.
What is ORKA's 52-week high and low?
Oruka Therapeutics's 52-week high is $115.52 and its 52-week low is $25.23. Its latest price of $96.32 on Nov 17, 2026 is 16.6% below the high.
What is ORKA's beta?
Oruka Therapeutics's 1-year beta against the S&P 500 is 1.48, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 36.4%.
Is the ORKA chart free?
Yes. Advanced Charting for ORKA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ORKA pages: Overview, Charting, Earnings, Forecast, Statistics